KT109（Cat No.:I007533）is a selective, covalent inhibitor of diacylglycerol lipase-β (DAGLβ), an enzyme involved in the biosynthesis of the endocannabinoid 2-arachidonoylglycerol (2-AG). By inhibiting DAGLβ, KT109 reduces 2-AG and downstream arachidonic acid-derived pro-inflammatory mediators, making it a valuable tool for studying lipid signaling and inflammation. KT109 has shown efficacy in preclinical models of inflammatory diseases and pain, offering insight into non-cannabinoid receptor-based modulation of the endocannabinoid system. Its high selectivity and irreversible mechanism provide precise biochemical inhibition, supporting its role in mechanistic studies and potential therapeutic exploration.